Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rania Rifaey

Anesthesiology Wallingford, CT Medical Doctor

NPI 1255666350 CMS profile 598622

863 N Main Street Ext Ste 200, Wallingford, CT 06492

Open in the dashboard

General payments

$4,971

53 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rania Rifaey of Wallingford, CT is reported in the CMS Open Payments database as having received $4,971 across 53 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $30 2
2024 General $18 1
2023 General $89 4
2021 General $809 6
2020 General $1,725 13
2019 General $2,300 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rania Rifaey
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Rania Rifaey were reported at $30. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Rania Rifaey Anesthesiology median Middle half National median
2019 $2,300 $72 $23–$151 $163
2020 $1,725 $36 $17–$120 $114
2021 $809 $49 $21–$135 $132
2022 $0 $52 $22–$144 $149
2023 $89 $53 $23–$143 $160
2024 $18 $55 $25–$150 $164
2025 $30 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $1,976 14 payments
  2. Nevro Corp. $1,726 18 payments
  3. Medtronic USA, Inc. $544 8 payments
  4. SPR Therapeutics, Inc $508 2 payments
  5. Orthofix Medical, Inc. $48 3 payments
  6. Relievant Medsystems, Inc. $31 1 payment
  7. Zimvie Inc. $24 1 payment
  8. Stryker Corporation $24 1 payment
  9. SI-BONE, Inc. $20 1 payment
  10. DePuy Synthes Sales Inc. $19 1 payment
  11. Other $51 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,436 16 payments
  2. Food and Beverage $1,535 37 payments
Products named General payments · program years 2019–2025
  1. Senza Spinal Cord Stimulation System $1,714 17 payments
  2. Proclaim Family of SCS IPGs $1,441 7 payments
  3. SPRINT PNS System $508 2 payments
  4. INTELLIS $488 6 payments
  5. Neuromodulation Dspsbls and Accs $265 5 payments
  6. Proclaim IPG $251 1 payment
  7. RESTORE $49 1 payment
  8. Physio-Stim $39 2 payments
  9. Intracept Pain $31 1 payment
  10. Intracept Pain $31 1 payment
  11. Other $314 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

1,080

Median for Anesthesiology: 322

Drug cost

$26,003

Median for Anesthesiology: $8,738

Branded share of claims

2%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine Generic 43 $11,326
Gabapentin Generic 514 $7,179
Pregabalin Generic 192 $4,322
Tizanidine Hcl Generic 51 $704
Cyclobenzaprine Hcl Generic 60 $576
Methylprednisolone Generic 69 $426
Celecoxib Generic 14 $413
Amitriptyline Hcl Generic 24 $366
Tramadol Hcl Generic 40 $323
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 22 $250

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$159,002

Of which drugs: $1,034

Medicare patients

279

Average age 78

Services billed

1,847

182 women, 97 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 31%
Ischemic heart disease 28%
Chronic kidney disease 27%
Depression 23%
Atrial fibrillation 22%
Osteoporosis 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 51 81 $63
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 135 212 $60
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 102 273 $25

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

53 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record